



Data Safety Monitoring Board Communication

Date: 03 September 2013

TO: TIRCON2012V1 study Investigators

FROM: Dr. Anna Rozova, Director, Medical Safety. ApoPharma Inc.

RE: Clinical study protocol TIRCON2012V1: A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN)

DSMB safety review meeting of 06 Aug 2013

The first meeting of the independent Data Safety Monitoring Board (DSMB) for the clinical study TIRCON2012V1 - A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN) was held on the 06th of August 2013.

The meeting was scheduled and held according to the planned periodic review of safety data. This review encompassed the safety data collected from the beginning of the study until the cut off period of 09 July 2013, and any late-breaking safety information received between the cutoff point and the date of the meeting.

The DSMB reviewed the above-referenced data and unanimously recommended continuation of the trial without modification. DSMB did not identify any issues requiring premature unblinding, suspension or termination of the study.

The next planned interim review meeting is planned for the beginning of January 2014.